Bristol-Myers convinces NICE to U-turn on first-line Yervoy
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has managed to convince NICE, the health technology appraisal institute for England and Wales, to do a U-turn on its decision not to allow melanoma drug Yervoy (ipilimumab) to be used first line at the expense of the National Health Service (NHS). In final draft guidance, the institute has given Yervoy the nod following evaluation of new analyses submitted by the company.